NASDAQ : HRTX

Heron Therapeutics, Inc.

$0.4592 USD

$0.0 (0.75%)

Volume
2.19M
Average Volume
3.35M
Market Capitalization
$86.92M
P/E Ratio
-2.59
Dividend Yield
0.00%
Price Target
$6.00
Year High
$1.93
Year Low
$0.38
Day High
—
Day Low
—
Payout Ratio
$0.00
Current Ratio
$2.53
Company Overview

NASDAQ

Craig Alexander Collard

Biotechnology

Healthcare

HRTX

128

US

USD

https://www.herontx.com

858 251 4400

427746102

0000818033

Liquidity Metrics

15.50

2.53

1.51

0.29

0.00

Sales & Valuation

$154.9M

0.58

9.53

-4.17

-0.11

Profitability

-$0.12

-$20.2M

-20.53%

-20.53%

-1115.29%

-12.57%

P/E Metrics

-2.59

0.01

0.01

Analyst Price Target & Rating

$6.00

$9.00

$5.00

Sell

2/5

19 Analysts

-92.35%

Financial Health Scores

-9.97

3/9

$138.47M

$246.22M

$237.08M

-$27.04M

Key Metrics (TTM)

$201.79M

1.34

-8.36

2.53

-1115.29%

-6.72%

-35.79%

-24.18%

903 days

Company Executives
Name Title
Craig Alexander Collard Chief Executive Officer & Director
William Forbes D. Executive Vice President & Chief Development Officer
John C. Arthur Senior Vice President of Manufacturing Development
Melissa Jarel Vice President of Legal
Mark E. Hensley Executive Vice President & Chief Operating Officer
Robert Sullivan Chief Commercial Officer
Jeff Cohn Executive Director, Assistant General Counsel & Assistant Secretary
Ryan Craig Vice President of Marketing
Brett Fleshman Chief Business Officer
John Aiken Executive Director of People Management & Training
Kevin Warner Senior Vice President of Medical Affairs Strategy & Engagement
Ira Duarte Executive Vice President & Chief Financial Officer
Poll Results

No votes yet today — be the first to share your view!

About Heron Therapeutics, Inc. (NASDAQ:HRTX) Stock

Heron Therapeutics, Inc. is a biotechnology firm dedicated to creating innovative therapies for critical patient requirements. The company leverages its proprietary Biochronomer drug delivery platform, an advanced system that enables the controlled release of various short-acting pharmacological agents. This technology ensures therapeutic concentrations are maintained for periods ranging from days to weeks following just a single administration. Among its commercialized products is SUSTOL (granisetron), an extended-release injectable designed to prevent both immediate and delayed nausea and vomiting triggered by moderately emetogenic chemotherapy, or specific anthracycline and cyclophosphamide combination therapies. Additionally, Heron markets CINVANTI, an intravenous formulation of aprepi ... tant. CINVANTI, which acts as a substance P/neurokinin-1 receptor antagonist, is indicated for the prevention of acute and delayed chemotherapy-induced nausea and vomiting in patients undergoing highly or moderately emetogenic cancer chemotherapy. The company's development pipeline includes ZYNRELEF, an innovative dual-acting local anesthetic that combines bupivacaine, a local anesthetic, with a low dose of the nonsteroidal anti-inflammatory drug (NSAID) meloxicam in a single fixed-dose formulation. Also in development is HTX-019, an experimental therapy aimed at preventing postoperative nausea and vomiting (PONV). Furthermore, HTX-034 is being advanced for postoperative pain management and is currently undergoing Phase Ib/II clinical trials, notably in patients recovering from bunionectomy procedures. Originally established in 1983 as A.P. Pharma, Inc., the company adopted its current name, Heron Therapeutics, Inc., in January 2014. Its corporate headquarters are situated in San Diego, California.

Heron Therapeutics to Report Second Quarter 2026 Financial Results on Monday, August 10, 2026

2026-07-27 08:30:00

CARY, N.C., July 27, 2026 (GLOBE NEWSWIRE) -- Heron Therapeutics, Inc. (Nasdaq: HRTX) (“Heron” or the “Company”), a commercial-stage biotechnology company, today announced that the Company will host a conference call and live webcast on Monday, August 10, 2026, at 8:30 a.m. ET to report second quarter financial results and discuss recent business highlights.

New Strong Sell Stocks for July 15th

2026-07-15 07:26:08

BV, RAIL and HRTX have been added to the Zacks Rank #5 (Strong Sell) List on July 15th, 2026.

U.S. District Court Issues Decision Regarding CINVANTI® Patents

2026-06-02 08:12:00

CARY, N.C., June 02, 2026 (GLOBE NEWSWIRE) -- Heron Therapeutics, Inc. (Nasdaq: HRTX) (“Heron” or the “Company”), a commercial-stage biotechnology company, today announced that the U.S. District Court for the District of Delaware issued a decision in the patent litigation between Heron and Azurity Pharmaceuticals, Inc., Azurity Pharmaceuticals India LLP f/k/a Slayback Pharma India LLP, and Slayback Pharma LLC (“Azurity”), with respect to CINVANTI® (aprepitant) injectable emulsion, holding that the asserted claims of Company's U.S. Patent Nos. 12,115,255 and 12,290,520 are invalid.

Heron Therapeutics, Inc. (HRTX) Q1 2026 Earnings Call Transcript

2026-05-11 13:20:47

Heron Therapeutics, Inc. (HRTX) Q1 2026 Earnings Call Transcript

Heron Therapeutics Q1 Earnings Call Highlights

2026-05-11 11:08:39

Heron Therapeutics NASDAQ: HRTX said first-quarter 2026 results were pressured by seasonal factors and severe winter weather, but management reaffirmed its full-year outlook and pointed to improving momentum exiting the quarter.

Heron Therapeutics (HRTX) Reports Q1 Earnings: What Key Metrics Have to Say

2026-05-11 10:31:24

The headline numbers for Heron Therapeutics (HRTX) give insight into how the company performed in the quarter ended March 2026, but it may be worthwhile to compare some of its key metrics to Wall Street estimates and the year-ago actuals.

Heron Therapeutics (HRTX) Reports Q1 Loss, Lags Revenue Estimates

2026-05-11 10:11:14

Heron Therapeutics (HRTX) came out with a quarterly loss of $0.04 per share versus the Zacks Consensus Estimate of a loss of $0.03. This compares to earnings of $0.01 per share a year ago.

Heron Therapeutics Announces First Quarter 2026 Financial Results and Reaffirms Guidance

2026-05-11 08:00:00

CARY, N.C., May 11, 2026 (GLOBE NEWSWIRE) -- Heron Therapeutics, Inc. (Nasdaq: HRTX) (“Heron” or the “Company”), a commercial-stage biotechnology company, today announced financial results for the three months ended March 31, 2026, and highlighted recent corporate updates.

Frequently Asked Questions

What is the current Heron Therapeutics, Inc. (HRTX) stock price?

Heron Therapeutics, Inc.(NASDAQ:HRTX) stock price is $0.4592 in the last trading session. During the trading session, HRTX stock reached the peak price of $1.93 while $0.38 was the lowest point it dropped to. The percentage change in HRTX stock occurred in the recent session was 0.75% while the dollar amount for the price change in HRTX stock was $0.0.

HRTX's industry and sector of operation?

The NASDAQ listed HRTX is part of Biotechnology industry that operates in the broader Healthcare sector.

Who are the executives of HRTX?

Craig Alexander Collard | Chief Executive Officer & Director
William Forbes D. | Executive Vice President & Chief Development Officer
John C. Arthur | Senior Vice President of Manufacturing Development
Melissa Jarel | Vice President of Legal
Mark E. Hensley | Executive Vice President & Chief Operating Officer

How many employees does HRTX have?

Number of HRTX employees currently stands at 128. HRTX operates from 4242 Campus Point Court, Cary, NC 92121, US.

Link for HRTX official website?

Official Website of HRTX is: https://www.herontx.com

How do I contact HRTX?

HRTX could be contacted at phone #858 251 4400 and can also be accessed through its website. HRTX operates from 4242 Campus Point Court, Cary, NC 92121, US.

How many shares of HRTX are traded daily?

The average number of HRTX shares traded daily for last 3 months was 3.35M.

What is the market cap of HRTX currently?

The market value of HRTX currently stands at $86.92M with its latest stock price at $0.4592